-
The management of a patient with suspected fetal macrosomia remains an enigma. Not being able to come up with a consistent plan of management for macrosomia is compounded by our inability to reliably predict it.
-
This is a small U.S.-based clinical trial of 23 adolescent women (ages 14-18) randomized to levonorgestrel-releasing vs Copper T intrauterine device (IUD).
-
-
[Editor's note: Look to the July 2010 issue for the second of this two-part series for information on SWAP, an online database developed by the California STD/HIV Prevention Training Center.]
-
Trichomoniasis is the most common curable sexually transmitted disease (STD) in young, sexually active women. An estimated 7.4 million new cases occur each year in women and men, according to the Centers for Disease Control and Prevention (CDC).
-
As a clinician who counsels on contraceptive choice, how can you determine if a woman is a likely candidate for the contraceptive vaginal ring (NuvaRing, Merck & Co., Whitehouse Station, NJ)? New research suggests that young women who report tampon use are more likely to choose the contraceptive vaginal ring over oral contraceptives as their initial birth control method.
-
Sexuality is a normal part of adolescent development. Though sexual behaviors can lead to adverse reproductive health outcomes, most adolescents will become sexually active during their teen-age years, which makes interventions that promote or enhance sexual health in adolescents increasingly important.
-
The last time your teen-age male patient came to the adolescent clinic, he left with a bag of male condoms. However, when he returns to be tested for sexually transmitted diseases (STDs), he tells you he hasn't used the condoms. Why?
-
In March 2010, President Barack Obama signed the Patient Protection and Affordable Care Act into law, setting the wheels in motion for sweeping health care reform. Now that the dust has settled, what are the implications for those who provide reproductive health services, as well as those who receive them?
-
Examining the three arms of the ACCORD trial; and FDA Actions: clopidogrel, dexlansoprazole, and tamsulosin.